|1.||Masunaga, Shin-Ichiro: 1 article (09/2004)|
|2.||Ono, Koji: 1 article (09/2004)|
|3.||Kinashi, Yuko: 1 article (09/2004)|
|4.||Nagasawa, Hideko: 1 article (09/2004)|
|5.||Suzuki, Minoru: 1 article (09/2004)|
|6.||Uto, Yoshihiro: 1 article (09/2004)|
|7.||Sakurai, Yoshinori: 1 article (09/2004)|
|8.||Hiraoka, Masamitsu: 1 article (09/2004)|
|9.||Maruhashi, Akira: 1 article (09/2004)|
|10.||Nagata, Kenji: 1 article (09/2004)|
09/01/2004 - "Based on the data of the pharmacokinetics analyses, TX-2060 was chosen for a subsequent tumor-irradiation study. "
09/01/2004 - "10B-carrier, with a gamma-ray-sensitizing effect on tumor cells as well as the potential to keep 10B in tumors and sensitize tumor cells more markedly than conventional 10B-carriers, such as TX-2060, is a promising candidate for use in BNCT."
09/01/2004 - "Further, TX-2060 clearly exhibited a radio-sensitization effect with gamma-rays, not only on total cells but also on Q and hypoxic tumor cells, which was not achieved by BSH. "
09/01/2004 - "In addition, TX-2060 had a significantly stronger radio-sensitization effect with reactor thermal neutron beams than BSH on both total and Q cells in solid tumors. "
09/01/2004 - "10B distribution analyses in tumors, muscles, blood and liver indicated that TX-2060 has the most favorable characteristics for concentrating a sufficient amount of 10B in tumors and maintaining a high enough 10B concentration during irradiation. "